RecruitingPhase 3NCT06684847

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

Studying Primary Sjögren disease

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: argenx
Intervention: Efgartigimod PH20 SC(biological)
Enrollment: 580 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2028

Study locations (30)

One of a Kind Clinical Research Center LLC, Scottsdale, Arizona, United States
Arizona Arthritis & Rheumatology Research, PLLC, Sun City, Arizona, United States
Arizona Arthritis & Rheumatology Research, PLLC, Tucson, Arizona, United States
Providence Medical Foundation, Fullerton, California, United States
Stanford University School of Medicine, Stanford, California, United States
University of Colorado, Aurora, Colorado, United States
Clinical Research of West Florida, Inc., Clearwater, Florida, United States
Centre for Rheumatology, Immunology and Arthritis, Fort Lauderdale, Florida, United States
Finlay Medical Research Corp, Greenacres City, Florida, United States
University of Florida College of Medicine Jacksonville, Jacksonville, Florida, United States
Life Clinical Trials, Margate, Florida, United States
Clinical Research of West Florida, Inc., Tampa, Florida, United States
Conquest Research, Winter Park, Florida, United States
Piedmont Healthcare, Inc., Atlanta, Georgia, United States
St. Luke's Clinic - Rheumatology, Boise, Idaho, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06684847 on ClinicalTrials.gov

Other trials for Primary Sjögren disease

Additional recruiting or active studies for the same condition.

See all trials for Primary Sjögren disease →

← Back to all trials